Watch Entire Prescribing Data OPDIVO® (nivolumab) is indicated with the treatment of adult patients with classical Hodgkin lymphoma (cHL) which has relapsed or progressed right after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or soon after 3 or more str